Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and
conditions caused by blood clots. Although clopidogrel works in many individuals, some people
do not respond as well to this drug. The variation in treatment response may be linked to
genetics. This study will examine the effects of clopidogrel in a population in which
sequencing for certain genes has been performed in order to determine the role that genes
play in the response to various clopidogrel maintenance doses.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
Food and Drug Administration (FDA) National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Institute of General Medical Sciences (NIGMS)